LONDON, UK / ACCESSWIRE / December 19, 2017 / Active-Investors issued a free report on The Procter & Gamble Co. (NYSE: PG) ("P&G"), which is readily accessible upon registration at www.active-investors.com/registration-sg/'symbol=PG as the Company's latest news hit the wire. On December 15, 2017, the Company announced the certified results of the voting held at its 2017 Annual Shareholders Meeting (ASM) on October 10, 2017, with regards to the election of directors to its Board. The Company also shared the action plan based on the shareholders' input received during the 2017 ASM. Sign up now for our free research reports at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, The Procter & Gamble most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at:
Addition of Nelson Peltz to Company's Board
The results of the certified count have led to the election of all 11 candidates nominated by the Company to the Board. They include Francis Blake, Angela Braly, Amy Chang, Kenneth Chenault, Scott Cook, Terry Lundgren, W. James McNerney, David Taylor, Margaret Whitman, Patricia Woertz, and Ernesto Zedillo.
The certified count indicated that Nelson Peltz, who has been engaged in an active proxy war with the Company to gain a seat on the Company's Board, has received 50% of the total votes. The votes in his favor were quite close to the number of votes received by P&G's candidate Ernesto Zedillo. Considering the various discussions with Nelson regarding a Board seat and the close margin of votes, the Company has decided to appoint him as a Director. His appointment as Director to the Company's Board is effective from March 01, 2018 onwards. The Company feels that although it may not agree with Nelson on matters like taking on excessive leverage, reducing R&D spending, splitting of the Company or moving the Company out of Cincinnati, it is committed to working with Nelson in the best interests of its shareholders.
The Company has also committed that it will nominate Nelson as the Company's representative during the election for the Board's seats at the 2018 ASM.
One of the major inputs received from many of its shareholders during the proxy war was the need for the Company to refresh its Board's composition. The Company has decided to act on the input and after an extensive search, appointed Joseph Jimenez, the CEO of Novartis to the Company's Board. His appointment is effective March 01, 2018, and brings with him extensive experience in consumer products, healthcare, and international business, which will greatly benefit P&G.
Additionally, the Company's shareholders had indicated that changes need to be made in its executive compensation practices. Accordingly, the Company has modified its Performance Stock Program to include relative sales growth metrics and a Total Shareholder Return modifier to ensure that awards match performance and are in-line with external competitive benchmarks. The Company plans to implement the changes in executive compensation in fiscal year 2018-2019 and is reviewing requisite changes.
The Company has shared that its business strategy and plans are working and delivering results. However, it is implementing various steps to ensure continued productivity to fuel future growth and increase returns to its shareholders.
About Nelson Peltz and his proxy war for a Board seat
Nelson Peltz is the CEO and Founding Partner of Trian Fund Management, L.P, which he founded in 2005. Trian Fund owns approximately $3.5 billion of P&G's shares. Trian Fund filed a preliminary proxy statement with the US Securities and Exchange Commission (SEC) in July 2017 for the election of Nelson to P&G's Board at the 2017 ASM. Trian Fund believed that being one of the largest shareholders of the Company it was disappointed with the Company's performance in the last decade and wanted to assist the Company with some of the challenges faced by it. The main areas of concern that Trian Fund had with P&G were poor returns to its shareholders, declining market share, excessive costs and a bureaucratic environment. As a Board Member, Trian Fund believed that Nelson Peltz's vast experience in turning around consumer companies and increase long-term shareholder value would be of great value to P&G.
Following the proxy voting at the Company's 2017 ASM on October 10, 2017, the preliminary vote count indicated that Nelson had not been elected to the Board. However, these had been preliminary results and these results needed to be certified by the independent Inspector of Elections. On November 15, 2017, P&G had disclosed that the results of preliminary vote count tabulated by IVS Associates, Inc., the Independent Inspector of Elections, had indicated that Nelson lead in the Director votes by a margin of approximately 0.0016% of shares compared to votes for Ernesto Zedillo. At that time, these results could have been reviewed and challenged by both P&G and Trian Fund. On November 22, 21017, however, the Company had said that it would not challenge the results of the preliminary vote count by IVS Associates and would await the final certified results. On the same day, Trian Fund had responded saying that irrespective of the correctness of the results and P&G's efforts to keep Nelson out of the Company's Board, the Company's Board should revisit its decision and offer a Board seat to Nelson immediately. Trian Fund's rationale had been that given the number of votes received by Nelson from P&G's shareholders, the shareholders wanted him on the Company's Board.
About The Procter & Gamble Co.
Cincinnati, Ohio-based P&G was founded by William Procter and James Gamble in 1837. It is one of the largest multinational consumer goods conglomerate with operations spread across 70 countries. Some of the leading consumer brands owned by the Company include Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®.
Stock Performance Snapshot
December 18, 2017 - At Monday's closing bell, The Procter & Gamble's stock slightly fell 0.01%, ending the trading session at $91.88.
Volume traded for the day: 7.40 million shares, which was above the 3-month average volume of 7.13 million shares.
Stock performance in the last month - up 2.95%; previous six-month period - up 2.51%; past twelve-month period - up 8.50%; and year-to-date - up 9.28%
After yesterday's close, The Procter & Gamble's market cap was at $234.34 billion.
Price to Earnings (P/E) ratio was at 24.55.
The stock has a dividend yield of 3.00%.
The stock is part of the Consumer Goods sector, categorized under the Personal Products industry. This sector was up 0.8% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.